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Abstract
Laboratory diagnosis of acute infection of hepatitis E virus (HEV) is commonly based on the detection of HEV RNA, IgM and/
or rising IgG levels. However, the profile of these markers when the patients present have not been well determined. To
clarify the extent of misdiagnosed sporadic hepatitis E in the initial laboratory detection, serial sera of 271 sporadic acute
hepatitis cases were collected, detected and the dynamics of each acute marker during the illness course were analyzed. 91
confirmed cases of hepatitis E were identified based on the presentation of HEV RNA, IgM or at least 4 fold rising of IgG
levels. 21 (23.1%) hepatitis E cases were false negative for the viral RNA and 40 (44.0%) for rising IgG, because occurrence of
these markers were confined to acute phase of infection and viremia had already subsided and antibody level peaked when
these patients presented. IgM was detected in 82 (90.1%) cases. It is the most prevalent of the three markers, because the
antibody persisted until early convalescence. Nine cases negative for IgM were positive for rising IgG and one was also
positive for the viral RNA; all of these nine cases showed high avid IgG in their acute phase sera, which indicated re-
infection. In summary, it is not practicable to determine the true occurrence of sporadic hepatitis E. Nevertheless, it could be
closely approximated by approach using a combination of all three acute markers.
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Introduction
Hepatitis E Virus (HEV) has been recognized to be a major
cause of outbreaks associated with fecal contamination of drinking
water for decades [1,2,3,4,5,6,7]. As better diagnostic assays
become commercially available, this pathogen is now recognized
also as a major etiologic agent of sporadic acute hepatitis in
endemic countries and autochthonous acute hepatitis cases in
Western Europe and industrialized countries of East Asia [1,8].
Hepatitis E appears to be rare in the United States, despite the
finding of relatively high seroprevalence in various populations
[9,10,11,12]. The reason is not well understood, but it is at least
partly because of a lack of a FDA-licensed diagnostic assay.
The virus afflicting humans consists of a single serotype and 4
major genotypes. Genotypes 1 and 2 have only been isolated from
humans and are mainly distributed in developing countries. In this
setting they cause large water borne outbreaks and sporadic cases
and are associated with a high mortality among pregnant women
and individuals with chronic liver disease [13,14,15]. Genotypes 3
and 4 are zoonotic with swine being the principal reservoir. The
virus is widely distributed, causing limited food-borne outbreaks
and sporadic cases, affecting mainly middle aged and elderly males
[1,16,17].
Hepatitis E is diagnosed by detecting viral RNA (RT-PCR) in
the serum and/or feces during the incubation period or early acute
phase of disease, or, more commonly, by demonstrating IgM anti-
HEV or a rising titer of IgG anti-HEV in the serum during the late
acute phase or convalescent phase of the illness [8]. While
generally considered to be specific, the sensitivity of these markers
has not been determined. Consequently, the proportion of
hepatitis E cases that has missed diagnosis is uncertain. To clarify
the extent of misdiagnosed sporadic hepatitis E in the initial
laboratory detection, serial sera of 271 sporadic acute hepatitis
cases were collected, detected and the dynamics of acute markers
during the illness course were analyzed.
Results
Diagnosis and Exclusion of Hepatitis E
1488 sporadic possible hepatitis cases presenting with com-
plaining of fatigue and/or loss of appetite for at least 3 days were
enrolled (Figure 1). Serial sera were collected and detected for
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13560HEV RNA, IgM and IgG levels from 271 acute hepatitis cases
whose liver injury were evidenced on presentation by ALT levels
$2.5 ULN. 91 cases of hepatitis E were confirmed based on the
presentation of at least 4 fold rising of IgG levels, RNA, IgM or
low avidity IgG (Figure 1 and Figure 2). They include 3 who were
co-infected with HBV, being also positive for HBc IgM.
Among 91 hepatitis E cases, acute marker profiles of 82 cases
are compatible with primary infection, reflecting a vigorous IgM
response, a relatively weak and transient IgG response with
production of low avidity IgG and a relatively protracted viremia.
The remaining 9 cases were positive for rising IgG levels and one
was also positive for RNA, but all were negative for both IgM and
low avidity IgG (Table 1). Such restricted profiles are compatible
with re-infection [18,19]. Of the 71 viral RNA positive cases, 70
underwent sequencing and 66 (94.3%) were genotype 4, the
remaining 4 isolates were genotype 1.
One patient had marginal level of IgM anti-HEV on day 3 (with
IgM S/Co of 2.1) and day 26 (with IgM S/Co of 1.7), but negative
for HEV RNA. The IgG anti-HEV was at low level, had no
notable rising (3.8 Wu/ml on day 3 and 3.7 Wu/ml on day 26),
and the avidity were high (72.6% on day 3 and 79.0% on day 26).
Hence this case was defined as possible hepatitis E case.
The remaining 179 cases were negative for all three markers
simultaneously, hence they were diagnosed as non-E hepatitis,
included 2 cases positive for HAV IgM, 19 cases positive for HBc
IgM and 3 cases positive for HCV IgG.
Dynamics of acute markers during progression of illness
Table 2 summarized the prevalence of HEV RNA, IgM and
IgG in the paired samples from hepatitis E cases. When
presentation, HEV RNA, IgM and IgG were detectable in 68
(73.9%), 73 (79.4%) and 87 (94.6%) patients respectively. HEV
RNA in most patients (89.7%, 61/68) converted to negative in the
second samples. Because levels of HEV IgM already peaked when
patients presented and the antibody persisted for longer period
than the other markers, it is most commonly detected among
hepatitis E patients and prevalence of the marker in the acute
samples (79.4%) is similar to that in the convalescent samples
(87.0%). The IgG anti-HEV can be detected in all hepatitis E
patients, most (94.6%, 87/92) had reached high levels when their
first presentation (Table 2).
Figure 3 shows ALT levels, prevalence of RNA and levels of
IgM and IgG in serial sera taken from hepatitis E cases. It was
evident that ALT levels were declining, viremia was subsiding
and antibody response was already initiated, when these patients
presented. Most patients achieved normalization of ALT levels
and virus clearance within 4 weeks of onset of symptoms. HEV
IgM levels already peaked when patients presented and
Figure 1. Flowchart of acute hepatitis patients diagnosed. Among 1488 patients presenting with fatigue and loss of appetite for no less than
3 days, 91 were diagnosed as hepatitis E, with a positive finding for at least one of the three HEV acute markers. Noted that false negative for any one
of the acute viral markers was compensated for by a positive finding for one or both or the other markers.
doi:10.1371/journal.pone.0013560.g001
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declined rapidly thereafter, falling below the cut off level (dotted
line) among most patients after 32 weeks. HEV IgG levels were
rising when patients presented. The antibody reached peak levels
about 4 weeks after onset of symptoms and maintained at high
levels for more than one year. The mean peak level of IgG in
h e p a t i t i sEc a s e sw a s9 4 . 4 62.4 Wu/ml. As contrast, among 118
non-hepatitis E patients who were positive with IgG anti-HEV
in the initial sample, the geometry mean concentration was
1.264.4 Wu/ml.
Performance of HEV Acute Markers
Diagnostic performance by rising IgG, RNA and IgM
individually and in combination was assessed (Table 3). For
calculation, the possible hepatitis E case was seemed as non-E
case. Sensitivity of rising IgG was 57.1%. The mean presentation
Table 1. Serological profiles of hepatitis E patients negative for IgM anti-HEV.
Case code Days after onset ALT (ULN) HEV RNA IgM (S/Co) IgG (Wu/ml) IgG avidity level (%)*
GY0630 10 28.7 2 0.0 0.5 ND
116 0.7 2 0.1 16.0 84.5
GY1311 8 2.6 2 0.0 0.6 79.2
24 2.3 2 0.4 6.0 84.9
GY1347 10 6.0 2 0.1 3.0 74.8
24 1.2 2 0.1 15.7 73.7
GY2835 3 7.0 2 0.1 ,0.03 N/A
24 0.8 2 1.0 0.7 82.8
GY3208 6 8.6 2 0.1 ,0.03 N/A
70 5.6 2 0.7 2.8 51.9
GY4209 4 6.0 2 0.0 0.2 107.5
29 1.2 2 0.1 1.0 70.0
GY5556 6 2.8 2 0.1 ,0.03 N/A
22 0.9 2 0.1 0.7 74.0
GY5761 5 5.5 2 0.0 1.5 81.0
39 0.5 2 0.7 15.7 65.2
GY3083 6 7.0 + 0.2 ,0.03 N/A
38 1.5 2 0.5 8.1 80.7%
*Low avidity antibody was indicated, when the residual antibody levels determined in the presence of 5 M urea was #50% of the corresponding control levels
concurrently determined in the absence of urea. ND, not detected. N/A, not applicable.
doi:10.1371/journal.pone.0013560.t001
Figure 2. Distribution of acute markers among hepatitis E patients. Among 271 patients presenting with fatigue and loss of appetite
attended by elevated serum ALT levels, 91 were diagnosed as having hepatitis E, with a positive finding for at least one of the three HEV acute
markers. Noted that false negative for any one of the acute viral markers was compensated for by a positive finding for one or both or the other
markers.
doi:10.1371/journal.pone.0013560.g002
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significantly earlier than that in cases negative for rising IgG,
which was 8.064.1 days (p,0.05). It indicated that false negative
of rising IgG associate with the delayed presentation. Sensitivity of
RNA was 78.0%. However, the false negative of RNA cannot be
contributed to the delay of presentation, because the RNA
negative patients first presented at 6.663.3 days, similar as that of
the RNA positive patients, 7.264.1 days (p.0.05). IgM afforded
the highest sensitivity (90.1%) of the three markers; false negative
was attributed to re-infection (Table 1). False negative for one
marker was compensated for by a positive finding for one or both
of the other markers, such that the sensitivity achieved by
combination of two markers was higher than that achieved by
either marker alone. The most complementary combination was
IgM and rising IgG, as the former covers all cases attributable to
primary infection and the latter covers all the cases attributable to
re-infection. Detection of either rising IgG or RNA is considered
Table 2. The prevalence of HEV RNA, IgM anti-HEV and IgG
anti-HEV in the paired sera of hepatitis E patients.
Present of markers (n=91)
1
st sample 2
nd sample RNA (%) IgM (%) IgG (%)
++ 7(7.7) 70(76.9) 86(94.5)
+ 2 61(67.0) 2(2.2)
£ 0(0.0)
2 + 3(3.3)
* 10(11.0) 5(5.5)
1
22 20(22.0) 9(9.9) 0(0.0)
*All three HEV RNA conversion cases were companied with anti-HEV IgM
positive conversion and IgG rising of $4 folds.
£Both were positive with HEV RNA.
1All negative for anti-HEV IgM in their first samples. One case was positive with
HEV RNA in first sample, and another case converted to anti-HEV IgM positive
on his second sample.
doi:10.1371/journal.pone.0013560.t002
Figure 3. Dynamics of acute markers in acute hepatitis. Serum samples were collected from 91 consecutive hepatitis E cases within the first
week of onset symptoms (n=59) and in the subsequent intervals after onset of symptoms from: one to 2 weeks (n=21); 2 to 4 weeks (n=55); 4 to 8
weeks (n=57); 8 to 16 weeks (n=22); 16 to 32 weeks (n=12) and 32 to 64 weeks (n=28). The levels of ALT(A), IgM anti-HEV(B) and IgG anti-HEV(D) of
the different groups of serum samples are shown as range (whiskers), interquartile (boxes) and median (line within the boxes) values. The occurrence
of the viral RNA(C) was shown as % prevalence (bar) and 95% confidence interval (whiskers). Dotted line represents the cutoff levels of IgM anti-HEV
(2.0 S/co).
doi:10.1371/journal.pone.0013560.g003
Infectious Markers in HE
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the present clinical setting was found to be 99.4%.
Discussion
HEV RNA is most commonly used as acute markers in routine
diagnosis of hepatitis E. IgM anti-HEV was increasingly used in
routine diagnosis since its reliability been dramatically increased
by using antigens that contained immono-dominant epitopes of
the virus and became commercially available in many countries
recently [18,19,20,21,22,23,24,25]. Rising IgG is less frequently
used, because it requires paired acute and convalescence serum
samples and provides a retrospective diagnosis. Low avidity IgG
was used to supplement findings by these three markers in some of
the cases, but it was not used as a primary diagnostic marker in the
present study, because its specificity has not yet been established.
However, most published data for the performance of these tests
were obtained based on samples confirmed by viral RNA, or
samples positive for at least one referenced assay [19,21,22,
23,24,25]. Hence the false negative rates of RNA tests cannot be
evaluated due to the sample selection strategies. In the mean time,
bias was unavoidable when sensitivity and specificity be evaluated,
because only samples from RNA detectable patients were selected.
As we are aware, the present is the first detailed study to assess the
performance of viral RNA, IgM and IgG anti-HEV markers in
laboratory diagnosis of sporadic hepatitis E. In this study, paired
acute and convalescent sera were obtained from acute hepatitis
cases.
To avoid sampling bias, study subjects were consisted of 271
cases of acute hepatitis consecutively presented over 12 months
period with complaints of constitutional signs, such as anorexia,
fatigue and etc., for 3 days and abnormal ALT levels $2.5 ULN.
The antigenic cross-reaction of human HEV with other pathogens
had not been reported, hence substantially rise of IgG anti-HEV
levels was generally considered as specific marker of acute
infection. However, false positive of RNA or IgM might occur
during operation. Therefore, diagnosis of hepatitis E based on
RNA or IgM was further confirmed by each other or by the
presence of low avidity IgG in acute phase serum. False positive
diagnosis by this approach is considered unlike. Exclusion of
hepatitis E was indicated by a negative finding for all the 3 markers
simultaneously. The fecal samples of the patients had not been
collected in this study. However, it is not likely that the sensitivity
of RNA detection would be higher if fecal samples be detected,
because the viral shedding period in the serum is usually similar to
or a little longer than that in the feces in most hepatitis E patients
[26].
91 patients were diagnosed with hepatitis E. Occurrence of
rising IgG and viremia was largely confined to the acute phase of
the infection during the first 4 weeks of onset of symptoms. Onset
of symptoms is innocuous, however, and presentation was delayed
to up to 21 days after onset of symptoms, when IgG antibody levels
had already peaked among 42.9% of patients and viremia had
subsided among 22.0% of patients. HEV IgM persisted for the
longest period until early convalescence about 16 weeks after onset
of symptoms and the marker was detected among 82 of the
patients. Detection of this marker was variously accompanied by at
least one of the other two markers or by the presence of low avidity
IgG antibody, reflecting a vigorous IgM response attended by
production of low avidity IgG which is compatible with primary
infection. The remaining 9 patients yielded a positive finding for
rising IgG and one was also positive for viremia, but all were
negative for both IgM and low avidity IgG. These acute marker
profiles reflect a weak IgM response attended by production of
avid IgG compatible with re-infection.
Under the above described clinical setting, it was evident that
diagnosis is best achieved by combination of all 3 markers.
Sensitivity achieved by this approach depends on clinical settings;
it is highly sensitive (100.0%) for cases attributed to primary
infection, but substantially lower (57.1%) for cases attributable to
re-infection, supposed due to the natural appearance of re-
infection as limited viral replication and limited induction of IgM
anti-HEV. In present study area, which is endemic for HEV
genotype 4, assume the sensitivity of rising IgG for re-infection is
similar as that for primary infection (i.e., 57.1%), and the
sensitivity of RNA for re-infection remains to be 11.1% (1/9),
then the combined sensitivity of RNA and rising IgG is 61.9%, the
expected number of re-infection is 14.5. Under this setting, the
expected hepatitis E among 271 acute hepatitis were 96.5 instead
of 91; the overall sensitivities of three acute markers were
estimated to be 73.6%, 85.0% and 53.9% for RNA, IgM and
rising IgG respectively. The sensitivity of combination of the three
acute markers is estimated to be 94.3% and negative predictive
value is 96.8%; failure of diagnosis occurred mainly in re-infection.
The approach in the present study affords a retrospective
diagnosis and is valuable for epidemiologic studies. In routine
practice, diagnosis is commonly based on detection of HEV RNA
Table 3. Sensitivity, specificity, positive and negative predictive value of HEV acute markers in diagnosis of acute hepatitis
patients.
Markers Sensitivity (n=91) Specificity (n=180)
(+) No.
Sensitivity (%)
(95%CI) (+) No.
Specificity (%)
(95%CI)
Positive predictive
value (%)(95%CI)
Negative predictive
value (%)(95%CI)
IgM 82 90.1(82.1–95.4) 1 99.4(96.9–100.0) 98.9(93.5–100.0) 95.2(91.1–97.8)
RNA 71 78.0(68.1–86.0) 0 100.0(98.0–100.0) 100.0(94.9–100.0) 90.0(85.0–93.8)
Rising IgG* 52 57.1(46.3–67.5) 0 100.0(98.0–100.0) 100.0(93.2–100.0) 82.2(76.5–87.0)
IgM or RNA 83 91.2(83.4–96.1) 1 99.4(96.9–100.0) 98.8(93.5–100.0) 95.7(91.8–98.1)
IgM or rising IgG 91 100(96.0–100.0) 1 99.4(96.9–100.0) 98.9(94.1–100.0) 100.0(98.0–100.0)
RNA or rising IgG 87 95.6(89.1–98.8) 0 100.0(98.0–100.0) 100.0(95.9–100.0) 97.8(94.5–99.4)
IgM, RNA, or rising IgG 91 100 (N/A)
& 1 99.4(96.9–100.0) 98.9(94.1–100.0) 100 (N/A)
&
*IgG anti-HEV seroconversion or showed a $4 fold rising of IgG anti-HEV.
&The sensitivity was set to be 100%, so the calculation for 95% CI is not applicable (N/A).
doi:10.1371/journal.pone.0013560.t003
Infectious Markers in HE
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associated with such routine approach is mainly due to re-infection
and sensitivity achieved by combination of both markers was
estimated to be 86.0%, which is very similar as that of 85.0%
achieved by HEV IgM alone. Sensitivity of HEV RNA and rising
IgG is substantially lower (73.6% and 53.9% respectively), because
viremia has already subsided and/or antibody levels had already
peaked in substantial number of patients at presentation. In low
endemic areas such as in Europe and the US, on the other hand,
sensitivity achieved by these markers is expected to be higher,
because re-infection would be less common.
In conclusion, the results show that it is not practicable to
determine the true occurrence of sporadic hepatitis E. Neverthe-
less, it could be closely approximated by approach using
combination of all three acute markers. Deviation from true
occurrence of hepatitis E is higher for high endemic than low
endemic areas.
Materials and Methods
Patients
In a group of community clinics and hospitals in rural townships
in eastern China, 1488 possible hepatitis patients who suffered
from fatigue and/or loss of appetite for at least 3 days and had an
elevated alanine-leucine transaminase (ALT) level were enrolled.
Informed consent in writing was obtained from each patient and
the study protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki. Independent Ethics Committee approval
was obtained from the Ethics Committee of Jiangsu Provincial
Center for Disease Control and Prevention.
Acute hepatitis was defined as an acute liver damage evidenced
on presentation by abnormal ALT levels $2.5 fold upper limit of
the normal levels (ULN). Acute hepatitis cases whose presented
sera were collected during time window of 3 to 21 days post-onset
and were collected for at least one another follow-up sera were
included for final analysis. Serial sera were collected from 271 of
such consecutive cases at 3 to 21 days after onset of symptoms
(6.763.7 days), and during convalescence 9 to 136 days after onset
of symptoms (25.6618.1 days). Additional serum samples were
collected from some of the patients (n=87) at later times up to one
year after onset of symptoms.
Confirmed hepatitis E cases were defined as: 1) at least 4 fold
rising IgG levels in paired sera; 2) RNA(+), confirmed by IgM(+);
or 3) IgM(+), confirmed by low avidity IgG in acute phase serum.
A possible hepatitis E case was defined as positive for HEV RNA
or IgM but can not be confirmed or excluded by antibody
dynamics.
Detection of HEV RNA
Serum samples were tested for the presence of the HEV RNA
by reverse-transcript PCR (RT-PCR) as previously described [27].
Briefly, total RNA was extracted from 200 ml of sample with
Trizol (Invitrogen). A 150-nt segment of open-reading frame 2
(ORF2), was amplified using primers E1 (59-CTGTTTAA(C/T)
CTTGCTGACAC-39, nt6260–6279) and E5 (59-(A/T)GA(A/G)
AGCCAAAGCACATC-39, nt6568–6551) in the first round of
PCR and primers E2 (59-GACAGAATTGATTTCGTCG-39,
nt6298–6316) and E4 (59-TG(C/T)TGGTT (A/G)TC(A/
G)TAATCCTG-3, nt6486–6467) in the second round. PCR
cycling conditions for both rounds consisted of 35 cycles of
denaturation at 94uC for 30 sec, annealing at 53uC for 30 sec, and
extension at 72uC for 40 sec.
Detection of antibodies against HEV
The levels of IgM or IgG antibody against HEV were
determined by commercial enzyme-linked immunosorbant assays
(ELISA) (Beijing Wantai Biological Pharmacy Enterprise Co.,
Ltd., Beijing, China) according to the manufacturer’s instructions.
These kits are based on a recombinant antigen contained
conformational immuno-dominant epitopes corresponding to
amino acid residues 394 to 606 of the major structural protein
specified by ORF 2 of the HEV genome [18,20,28,29]. IgG anti
HEV was expressed in world health organization unit (Wu) by
comparing with the level of an assay reference serum of 16.5 Wu/
ml and the limit of detection by the assay was 0.03 Wu/ml [30].
IgM anti-HEV was expressed as ratio to the cut-off value
recommended by the manufacturer (S/Co) with a positive being
S/Co $2. IgG anti-HEV avidity test was conducted on some
serum samples as previously described [18,31]. Briefly, serum
samples were titrated in parallel in the presence and absence of
5 M urea. Avidity of IgG anti-HEV was expressed as percent of
residual antibody levels determined in the presence of 5 M urea
relative to the corresponding levels determined in parallel in the
absence of 5 M urea. Presence of low avidity HEV IgG is
indicated, when residual antibody levels were #50% of control
values.
All specimens were also tested for IgM antibody against
hepatitis A virus (HAV-IgM), IgM antibody against hepatitis B
core protein (HBc-IgM), hepatitis B virus surface antigen (HBsAg),
and antibody against hepatitis C virus (HCV-Ab) using commer-
cial ELISA kits (Beijing Wantai Biological Pharmacy Enterprise
Co., Ltd., Beijing, China).
Statistical analysis
Data were expressed as mean 6 SD. Student’s t test was used
for continuous variables. Differences were considered to be
significant for P value ,.05. The statistical analysis was performed
using OpenEpi (Open Source Epidemiologic Statistics for Public
Health, Version 2.3. www.OpenEpi.com, updated 2009/20/05,
accessed 2009/01/10).
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